ESPR Q3 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$14M+275.9% YoY

Gross Profit

$9M61.4% margin

Operating Income

-$56M-386.9% margin

Net Income

-$69M-481.5% margin

EPS (Diluted)

$-2.62

QoQ Revenue Growth

-64.6%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$225M

Total Liabilities

$588M

Stockholders' Equity

-$363M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$4M	+275.9%
Gross Profit	$9M	$4M	+148.8%
Operating Income	-$56M	-$81M	+30.8%
Net Income	-$69M	-$85M	+18.8%

Revenue Segments

Collaboration Revenue

$4M52%

Royalty Revenue And Product Sales Bulk Tablets

$3M48%